Angiotensin II and progressive renal insufficiency

Current Hypertension Reports

Volumn 4, Issue 5, 2002, Pages 403-407

  Gaedeke, Jens ^a   Noble, Nancy A ^a   Border, Wayne A ^a  

^a Fibrosis Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; HUMAN; METABOLISM; REVIEW; SECRETION;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENDOTHELINS; HUMANS; KIDNEY FAILURE, CHRONIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, ANGIOTENSIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036779518     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0071-9     Document Type: Article

References (49)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329: 1456-1462.
2. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334: 939-945.
3. Ruggenenti P, Perna A, Gherardi G, et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354: 359-364.
4. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
6. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 35: 870-878.
7. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93: 2431-2437.
8. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993, 92: 1366-1372.
9. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997, 52: 1497-510.
10. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331: 1286-1292.
11. Border WA, Okuda S, Languino LR, et al.: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990, 346: 371-374.
12. Border WA, Noble NA, Yamamoto T, et al.: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360: 361-364.
13. Yamamoto T, Noble NA, Cohen AH, et al: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49: 461-469.
14. Gaedeke J, Peters H, Noble NA, Border WA: Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001, 135: 153-160.
15. Fern RJ, Yesko CM, Thornhill BA, et al.: Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999, 103: 39-46.
16. Inigo P, Campistol JM, Lario S, et al.: Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001, 12: 822-827.
17. Campistol JM, Inigo P, Jimenez W, et al.: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56: 714-719.
18. Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34: 818-823.
19. Laviades C, Varo N, Diez J: Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000, 36: 517-522.
20. Peters H, Border WA, Noble NA: Targeting TGF-beta over-expression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54: 1570-1580.
21. Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97: 8015-8020.
22. Miyajima A, Chen J, Lawrence C, et al.: Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000, 58: 2301-2313.
23. Siriwardena D, Khaw PT, King AJ, et al.: Human antitrans-forming growth factor beta(2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002, 109: 427-431.
24. Hill C, Flyvbjerg A, Rasch R, et al.: Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001, 170: 647-651.
25. Kagami S, Kuhara T, Okada K, et al.: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51664-671.
26. Hamano K, Iwano M, Akai Y, et al.: Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002, 39: 695-705.
27. Grandaliano G, Di Paolo S, Monno R, et al.: Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation 2001, 72: 1437-1443.
28. Ridker PM, Gaboury CL, Conlin PR, et al.: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993, 87: 1969-1973.
29. Vaughan DE, Rouleau JL, Ridker PM, et al.: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997, 96: 442-447.
30. Haraguchi M, Border WA, Huang Y, Noble NA: t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001, 59: 2146-2155.
31. Redmond EM, Cullen JP, Cahill PA, et al.: Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation 2001, 103: 597-603.
32. Huang Y Haraguchi M, Lawrence DA, et al.: A mutant, non-inhibitory plasminogen activator inhibitor-type1 (PAI-1) decreases matrix protein accumulation in anti-Thy1 nephritis [abstract]. J Am Soc Nephrol 2000, 11: 529a.
33. Oda T, Jung YO, Kim HS, et al.: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001, 60: 587-596.
34. Folkes A, Brown SD, Canne LE, et al.: Design, synthesis and In vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett 2002, 12: 1063-1066.
35. Muller DN, Mervaala EM, Schmidt F, et al.: Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000, 36: 282-290.
36. Fakhouri F, Placier S, Ardaillou R, et al.: Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001, 12: 2701-2710.
37. Benigni A Corna D, Maffi R, et al.: Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998, 54: 353-359.
38. Amann K, Simonaviciene A, Medwedewa T, et al: Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 2001, 12: 2572-2584.
39. MacFadyen RJ, Lee AF, Morton JJ, et al: How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999, 82: 57-61.
40. Satoh M, Nakamura M, Saitoh H, et al: Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002, 102: 381-386.
41. Silvestre JS, Heymes C, Oubenaissa A, et al: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99: 2694-2701.
42. Takeda Y Miyamori I, Yoneda T, et al: Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996, 81: 2797-2800.
43. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98: 1063-1068.
44. Fitzgibbon WR, Greene EL, Grewal JS, et al: Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 1999, 10: 814-821.
45. Brown NJ, Nakamura S, Ma L, et al: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58: 1219-1227.
46. Fiebeler A, Schmidt F, Muller DN, et al.: Mineralocorticoid receptor affects AP1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001, 37(2 Part 2): 787-793.
47. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-717.
48. Zannad F, Alla F, Dousset B, et al: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102: 2700-2706.
49. Bauersachs J, Fraccarollo D, Ertl G, et al: Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 2000, 102: 2325-2328.